Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUTENSIN vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension,Mild essential hypertension
Hypertension
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Extensively metabolized in the liver via deacetylation and hydrolysis; reserpine is metabolized by CYP3A4 and carboxyl esterase.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Protein binding is approximately 50-60%, primarily to albumin and alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Volume of distribution (Vd) is approximately 1.6 L/kg, indicating extensive tissue distribution and accumulation in adipose tissue. This high Vd contributes to the long half-life.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability is variable, estimated at approximately 50-60% due to extensive first-pass hepatic metabolism. Bioavailability is route-specific: oral only, as no parenteral formulations are clinically available.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: contraindicated due to thiazide component.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for use in children; safety and efficacy not established.
Not established; avoid use in children.
Start at lowest dose (0.5 tablet once daily); monitor for hypotension and electrolyte imbalance.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
May cause mental depression, especially in patients with history of depression,Use caution in patients with gastric ulcers (may increase gastric acid secretion),Avoid in patients undergoing electroconvulsive therapy (ECT),May cause hypotension and bradycardia,Discontinue 2 weeks before elective surgery
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to any component,Active peptic ulcer (may exacerbate),History of electroconvulsive therapy,Parkinsonism,Depression (especially with suicidal tendencies)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, tomatoes) unless advised by a doctor. Thiazide diuretics can cause potassium depletion, but reserpine may blunt this effect. Limit alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neural tube defects, cardiovascular anomalies) at high doses. Second and third trimesters: risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use during pregnancy, especially after 20 weeks gestation.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Reserpine is excreted into breast milk. M/P ratio: approximately 1:1. Potential for serious adverse effects in the nursing infant, including respiratory depression, bradycardia, and gastrointestinal disturbances. Breastfeeding is not recommended during maternal therapy with Rautensin.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Pregnancy-induced physiologic changes (increased plasma volume, renal clearance) may lower reserpine serum levels. However, due to teratogenic and neonatal risks, Rautensin is contraindicated in pregnancy. No dosing adjustments are recommended because use is not advised. Consider alternative antihypertensives with established safety profiles.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Rautensin is a combination of Rauwolfia alkaloids (e.g., reserpine) and a thiazide diuretic (e.g., bendroflumethiazide). It is rarely used today due to better-tolerated alternatives. Monitor for orthostatic hypotension, especially in elderly. Check serum potassium and uric acid regularly due to thiazide component. Reserpine can cause depression and nasal congestion; discontinue if depressive symptoms emerge. Avoid in patients with history of depression or peptic ulcer disease.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop abruptly as it may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness.,This medication can cause drowsiness; avoid driving until you know how it affects you.,Report any signs of depression, mood changes, or unusual tiredness.,Avoid alcohol and other sedatives; they can increase dizziness and drowsiness.,If you experience nasal congestion, it may be due to the medication; consult your doctor.,Regular blood tests are needed to monitor potassium and uric acid levels.,Use effective contraception if of childbearing age; discuss with your doctor.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUTENSIN vs ALDORIL 25, answered by our medical review team.
RAUTENSIN is a Antihypertensive that works by Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUTENSIN and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUTENSIN is: 1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUTENSIN and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUTENSIN is classified as Category C. Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neur. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.